Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

NCT ID: NCT05071716

Last Updated: 2025-07-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

524 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-07

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study RNLC3131 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatic Encephalopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rifaximin SSD-40mg IR

Group Type EXPERIMENTAL

Rifaximin SSD

Intervention Type DRUG

Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo Twice Daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rifaximin SSD

Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily

Intervention Type DRUG

Placebo

Placebo Twice Daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of liver cirrhosis with medically controlled ascites (\>30 days) not requiring therapeutic paracentesis (could have had paracentesis in the past).
* Conn (West Haven Criteria) score of \< 2.
* Mini-Mental State Examination (MMSE) score \> 24 at screening.
* ≥ 18 and ≤ 85 years of age.

Exclusion Criteria

* Active COVID-19 that is unresolved
* History of SBP
* History of EVB or AKI-HRS within 6 months
* History of OHE episode (Conn score ≥ 2)
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bausch Health Americas, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael Mader

Role: STUDY_DIRECTOR

Bausch Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Bausch Site 182

Dothan, Alabama, United States

Site Status

Bausch Site 129

Chandler, Arizona, United States

Site Status

Bausch Site 103

Peoria, Arizona, United States

Site Status

Bausch Site 180

Phoenix, Arizona, United States

Site Status

Bausch Site 153

Phoenix, Arizona, United States

Site Status

Bausch Site 248

Tempe, Arizona, United States

Site Status

Bausch Site 222

Tucson, Arizona, United States

Site Status

Bausch Site 150

Little Rock, Arkansas, United States

Site Status

Bausch Site 164

Bakersfield, California, United States

Site Status

Bausch Site 196

Chula Vista, California, United States

Site Status

Bausch Site 226

Chula Vista, California, United States

Site Status

Bausch Site 174

Escondido, California, United States

Site Status

Bausch Site 163

Fresno, California, United States

Site Status

Bausch Site 242

Garden Grove, California, United States

Site Status

Bausch Site 115

La Jolla, California, United States

Site Status

Bausch Site 141

Lancaster, California, United States

Site Status

Bausch Site 140

Los Angeles, California, United States

Site Status

Bausch Site 189

Los Angeles, California, United States

Site Status

Bausch Site 227

Orange, California, United States

Site Status

Bausch Site 199

Pasadena, California, United States

Site Status

Bausch Site 119

Redwood City, California, United States

Site Status

Bausch Site 102

Rialto, California, United States

Site Status

Bausch Site 177

San Diego, California, United States

Site Status

Bausch Site 171

San Francisco, California, United States

Site Status

Bausch Site 214

San Jose, California, United States

Site Status

Bausch Site 183

Upland, California, United States

Site Status

Bausch Site 143

Englewood, Colorado, United States

Site Status

Bausch Site 212

Littleton, Colorado, United States

Site Status

Bausch Site 151

Bristol, Connecticut, United States

Site Status

Bausch Site 220

Bradenton, Florida, United States

Site Status

Bausch Site 257

Cape Coral, Florida, United States

Site Status

Bausch Site 197

Cutler Bay, Florida, United States

Site Status

Bausch Site 249

Fort Myers, Florida, United States

Site Status

Bausch Site 173

Hialeah, Florida, United States

Site Status

Bausch Site 238

Hialeah Gardens, Florida, United States

Site Status

Bausch Site 235

Hollywood, Florida, United States

Site Status

Bausch Site 211

Homestead, Florida, United States

Site Status

Bausch Site 139

Inverness, Florida, United States

Site Status

Bausch Site 138

Jacksonville, Florida, United States

Site Status

Bausch Site 241

Lakewood Rch, Florida, United States

Site Status

Bausch Site 157

Miami, Florida, United States

Site Status

Bausch Site 255

Miami, Florida, United States

Site Status

Bausch Site 263

Miami, Florida, United States

Site Status

Bausch Site 264

Miami, Florida, United States

Site Status

Bausch Site 268

Miami, Florida, United States

Site Status

Bausch Site 224

Miami, Florida, United States

Site Status

Bausch Site 243

Miami, Florida, United States

Site Status

Bausch Site 166

Miami, Florida, United States

Site Status

Bausch Site 244

Miami, Florida, United States

Site Status

Bausch Site 266

Miami, Florida, United States

Site Status

Bausch Site 147

Miami, Florida, United States

Site Status

Bausch Site 218

Miami, Florida, United States

Site Status

Bausch Site 240

Miami, Florida, United States

Site Status

Bausch Site 186

New Port Richey, Florida, United States

Site Status

Bausch Site 213

Orlando, Florida, United States

Site Status

Bausch Site 267

Pembroke Pines, Florida, United States

Site Status

Bausch Site 256

Plantation, Florida, United States

Site Status

Bausch Site 272

Venice, Florida, United States

Site Status

Bausch Site 188

Weston, Florida, United States

Site Status

Bausch Site 219

Atlanta, Georgia, United States

Site Status

Bausch Site 215

Augusta, Georgia, United States

Site Status

Bausch Site 260

Dalton, Georgia, United States

Site Status

Bausch Site 126

Marietta, Georgia, United States

Site Status

Bausch Site 194

Chicago, Illinois, United States

Site Status

Bausch Site 120

Indianapolis, Indiana, United States

Site Status

Bausch Site 152

Clive, Iowa, United States

Site Status

Bausch Site 135

Iowa City, Iowa, United States

Site Status

Bausch Site 128

Topeka, Kansas, United States

Site Status

Bausch Site 124

Louisville, Kentucky, United States

Site Status

Bausch Site 237

Baton Rouge, Louisiana, United States

Site Status

Bausch Site 261

Houma, Louisiana, United States

Site Status

Bausch Site 134

Marrero, Louisiana, United States

Site Status

Bausch Site 118

New Orleans, Louisiana, United States

Site Status

Bausch Site 117

Baltimore, Maryland, United States

Site Status

Bausch Site 230

Glen Burnie, Maryland, United States

Site Status

Bausch Site 132

Boston, Massachusetts, United States

Site Status

Bausch Site 161

Boston, Massachusetts, United States

Site Status

Bausch Site 223

Boston, Massachusetts, United States

Site Status

Bausch Site 146

Burlington, Massachusetts, United States

Site Status

Bausch Site 233

New Bedford, Massachusetts, United States

Site Status

Bausch Site 136

Ann Arbor, Michigan, United States

Site Status

Bausch Site 265

Detroit, Michigan, United States

Site Status

Bausch Site 137

Detroit, Michigan, United States

Site Status

Bausch Site 149

Wyoming, Michigan, United States

Site Status

Bausch Site 253

Minneapolis, Minnesota, United States

Site Status

Bausch Site 271

Minneapolis, Minnesota, United States

Site Status

Bausch Site 148

Jackson, Mississippi, United States

Site Status

Bausch Site 178

Kansas City, Missouri, United States

Site Status

Bausch Site 251

East Brunswick, New Jersey, United States

Site Status

Bausch Site 191

Newark, New Jersey, United States

Site Status

Bausch Site 216

Albuquerque, New Mexico, United States

Site Status

Bausch Site 109

New York, New York, United States

Site Status

Bausch Site 225

New York, New York, United States

Site Status

Bausch Site 116

New York, New York, United States

Site Status

Bausch Site 217

Charlotte, North Carolina, United States

Site Status

Bausch Site 192

Durham, North Carolina, United States

Site Status

Bausch Site 269

Statesville, North Carolina, United States

Site Status

Bausch Site 245

Wilmington, North Carolina, United States

Site Status

Bausch Site 273

Wilmington, North Carolina, United States

Site Status

Bausch Site 114

Cleveland, Ohio, United States

Site Status

Bausch Site 154

Columbus, Ohio, United States

Site Status

Bausch Site 167

Dayton, Ohio, United States

Site Status

Bausch Site 185

Mentor, Ohio, United States

Site Status

Bausch Site 270

Moore, Oklahoma, United States

Site Status

Bausch Site 110

Philadelphia, Pennsylvania, United States

Site Status

Bausch Site 228

Pittsburgh, Pennsylvania, United States

Site Status

Bausch Site 250

Sayre, Pennsylvania, United States

Site Status

Bausch Site 104

Charleston, South Carolina, United States

Site Status

Bausch Site 184

Johnson City, Tennessee, United States

Site Status

Bausch Site 181

Nashville, Tennessee, United States

Site Status

Bausch Site 221

Austin, Texas, United States

Site Status

Bausch Site 122

Dallas, Texas, United States

Site Status

Bausch Site 144

Dallas, Texas, United States

Site Status

Bausch Site 133

Dallas, Texas, United States

Site Status

Bausch Site 107

Dallas, Texas, United States

Site Status

Bausch Site 123

Denison, Texas, United States

Site Status

Bausch Site 198

El Paso, Texas, United States

Site Status

Bausch Site 172

Fort Worth, Texas, United States

Site Status

Bausch Site 210

Fort Worth, Texas, United States

Site Status

Bausch Site 258

Harlingen, Texas, United States

Site Status

Bausch Site 170

Houston, Texas, United States

Site Status

Bausch Site 130

Houston, Texas, United States

Site Status

Bausch Site 158

Houston, Texas, United States

Site Status

Bausch Site 159

Houston, Texas, United States

Site Status

Bausch Site 229

Houston, Texas, United States

Site Status

Bausch Site 239

Houston, Texas, United States

Site Status

Bausch Site 252

Mesquite, Texas, United States

Site Status

Bausch Site 195

Pearland, Texas, United States

Site Status

Bausch Site 247

Sugar Land, Texas, United States

Site Status

Bausch Site 262

Sugar Land, Texas, United States

Site Status

Bausch Site 246

Texas City, Texas, United States

Site Status

Bausch Site 193

Waco, Texas, United States

Site Status

Bausch Site 127

Murray, Utah, United States

Site Status

Bausch Site 231

Manassas, Virginia, United States

Site Status

Bausch Site 175

Norfolk, Virginia, United States

Site Status

Bausch Site 113

Richmond, Virginia, United States

Site Status

Bausch Site 111

Richmond, Virginia, United States

Site Status

Bausch Site 155

Seattle, Washington, United States

Site Status

Bausch Site 105

Milwaukee, Wisconsin, United States

Site Status

Bausch Site 307

Concord, New South Wales, Australia

Site Status

Bausch Site 300

Kingswood, New South Wales, Australia

Site Status

Bausch Site 306

Bedford Park, South Australia, Australia

Site Status

Bausch Site 304

Box Hill, Victoria, Australia

Site Status

Bausch Site 302

Parkville, Victoria, Australia

Site Status

Bausch Site 305

Murdoch, Western Australia, Australia

Site Status

Bausch Site 303

Perth, Western Australia, Australia

Site Status

Bausch Site 202

Edmonton, Alberta, Canada

Site Status

Bausch Site 203

Toronto, Ontario, Canada

Site Status

Bausch Site 201

Toronto, Ontario, Canada

Site Status

Bausch Site 234

San Juan, , Puerto Rico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Canada Puerto Rico

References

Explore related publications, articles, or registry entries linked to this study.

Zacharias HD, Kamel F, Tan J, Kimer N, Gluud LL, Morgan MY. Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2023 Jul 19;7(7):CD011585. doi: 10.1002/14651858.CD011585.pub2.

Reference Type DERIVED
PMID: 37467180 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RNLC3131

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Rifaximin in Fatty Liver Disease
NCT01355575 TERMINATED PHASE4
Efficacy and Safety of Rifaximin in Treating MAFLD
NCT07185932 RECRUITING EARLY_PHASE1